Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
211At-MX35 F(ab')2
- Development stage
- Unknown
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intraperitoneal
01
Overview
211At-MX35 F(ab')2 is a radiolabeled monoclonal antibody fragment designed for targeted alpha-particle therapy, specifically for ovarian cancer. It comprises the murine IgG1-class monoclonal antibody MX35 (fragment F(ab')2), which binds to a cell-surface glycoprotein (95 kDa) that is highly expressed in approximately 90% of human epithelial ovarian cancers (OVCAR-3 cells). The antibody is labeled with astatine-211 (^211At), an alpha-emitting radionuclide, which enables localized delivery of cytotoxic radiation to microscopic tumor clusters while minimizing exposure to healthy tissue. The drug is administered intraperitoneally, allowing direct contact with residual cancer cells after chemotherapy. Developed at Memorial Sloan-Kettering Cancer Center, its clinical application is currently under investigation in open clinical trials in Denmark and Sweden, mainly focusing on safety, pharmacokinetics, and toxicity in relapsed or recurrent ovarian cancer[1][2][3][4][5].
- Other names
- 211-astatine-MX35 F(ab')2At-211-MX35-F(ab')2Astatine-211-MX35-F(ab')2
02
Targets
SLC34A2 (Sodium-dependent phosphate transporter type IIb)MUC16 (Mucin-16)
Beyond the preview
Go deeper on 211At-MX35 F(ab')2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 211At-MX35 F(ab')2.